Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7180736 | 0.78 | CA1 (0.48) | CA1CA2CA9LMNAKMT2A | |
| SCHEMBL10849987 | 0.76 | CA1 (0.52) | CA1CA2CA9LMNAKMT2A | |
| SCHEMBL6357382 | 0.76 | CA1 (0.52) | CA1CA2CA9LMNAKMT2A | |
| SCHEMBL6580142 | 0.76 | CA1 (0.47) | CA1CA2CA9LMNAKMT2A | |
| SCHEMBL19280567 | 0.76 | KMT2A (0.67) | CA1CA2CA9LMNAKMT2A | |
| SCHEMBL6912873 | 0.76 | POLB (0.62) | CA1CA2CA9LMNAKMT2A | |
| SCHEMBL196710 | 0.76 | TDP1 (0.52) | CA1CA2CA9LMNAKMT2A | |
| SCHEMBL6913682 | 0.76 | CA1 (0.47) | CA1CA2CA9LMNAKMT2A | |
| SCHEMBL534724 | 0.76 | GAA (0.54) | CA1CA2CA9LMNAKMT2A | |
| SCHEMBL28502902 | 0.76 | CA1 (0.47) | CA1CA2CA9LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110045397-A1 | CHARGE CONTROL AGENT AND RELATED ART | KURODA KAZUYOSHI | 2011-02-24 | — | — | US | disclosed |
| US-20090053641-A1 | CHARGE CONTROL AGENT AND RELATED ART | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1862860-A1 | CHARGE CONTROL AGENT AND RELATED TECHNIQUE | Orient Chemical Industries, Ltd. (JP) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053641-A1 | CHARGE CONTROL AGENT AND RELATED ART | H1-4, CECR2, DOT1L | CA1 1120/4885CA2 169/4885CA9 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.